deltatrials
Completed PHASE2 NCT00001564

A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas

Sponsor: National Cancer Institute (NCI)

Conditions Ewing's Sarcoma Rhabdomyosarcoma
Interventions CD40 Ligand E7 Peptide EF-1 Peptide EF-2 Peptide GM-CSF IL-2 IL-4 PXFK Peptide
Updated 23 times since 2017 Last updated: Nov 27, 2019 Started: Dec 23, 1996 Primary completion: Oct 25, 2007 Completion: Oct 25, 2007

A PHASE2 clinical study on Ewing's Sarcoma and Rhabdomyosarcoma, this trial is completed. The trial is conducted by National Cancer Institute (NCI) and has accumulated 23 data snapshots since 1996. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

23 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Dec 2019 — Jan 2021 [monthly]

    Completed PHASE2

  5. Nov 2019 — Dec 2019 [monthly]

    Completed PHASE2

▶ Show 18 earlier versions

  1. Oct 2019 — Nov 2019 [monthly]

    Completed PHASE2

  2. Sep 2019 — Oct 2019 [monthly]

    Completed PHASE2

  3. Jul 2019 — Sep 2019 [monthly]

    Completed PHASE2

  4. Jun 2019 — Jul 2019 [monthly]

    Completed PHASE2

  5. May 2019 — Jun 2019 [monthly]

    Completed PHASE2

  6. Apr 2019 — May 2019 [monthly]

    Completed PHASE2

  7. Mar 2019 — Apr 2019 [monthly]

    Completed PHASE2

  8. Feb 2019 — Mar 2019 [monthly]

    Completed PHASE2

  9. Jan 2019 — Feb 2019 [monthly]

    Completed PHASE2

  10. Dec 2018 — Jan 2019 [monthly]

    Completed PHASE2

  11. Nov 2018 — Dec 2018 [monthly]

    Completed PHASE2

  12. Oct 2018 — Nov 2018 [monthly]

    Completed PHASE2

  13. Sep 2018 — Oct 2018 [monthly]

    Completed PHASE2

  14. Aug 2018 — Sep 2018 [monthly]

    Completed PHASE2

  15. Jul 2018 — Aug 2018 [monthly]

    Completed PHASE2

  16. Jun 2018 — Jul 2018 [monthly]

    Completed PHASE2

  17. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

  18. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Dec 1996

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Bethesda, United States